T1 bladder cancer in Norway: treatment and survival

Figures & data

Table 1. Characteristics of T1 BC patients diagnosed from 2008-2012 in Norway.

	Men	Women	All
Sex	851 (77%)	257 (23%)	1,108
Median Age (IQR)	74 (65–81)	76 (66–83)	75 (65-81)
No previous cancer*	774 (91%)	222 (86%)	996 (90%)
Concomitant cis	124 (15%)	18 (7%)	142 (13%)
WHO High Grade (HG) at T1 diagnosis**	701 (91%)	202 (87%)	903 (90%)
Muscle in specimen at T1 diagnosis**	756 (89%)	207 (81%)	963 (87%)
ReTURB (<12 weeks)	440 (52%)	135 (53%)	575 (52%)
Early treatment
Conservative	645 (76%)	205 (80%)	850 (77%)
Without BCG
With BCG (<8 weeks)	127 (15%)	35 (14%)	162 (15%)
Cystectomy (<6 months)	79 (9%)	17 (7%)	96 (9%)
Delayed treatment
Conservative
Without BCG	370 (43%)	127 (49%)	497 (45%)
With BCG	221 (26%)	66 (26%)	287 (26%)
Cystectomy	68 (8%)	16 (6%)	84 (8%)
Death
BC-related Death	132 (16%)	43 (17%)	175 (16%)
Death of other causes	240 (28%)	59 (23%)	299 (27%)

*no other cancer within 5 years before BC diagnosis.

**in any TURB within 12 weeks since first T1 BC diagnosis.

Figure 1. Early and delayed treatment for T1 BC patients. Treatments considered are conservative treatments with and without BCG and RC. The histograms show the distribution of time since diagnosis of the respective delayed treatments.

Table 2. Patient characteristics for T1 BC patients receiving conservative treatment or cystectomy as early treatment. P-values indicate the effect of the respective patient characteristics on early BCG and RC treatment choice when compared to conservative treatment without BCG in a multivariable model.

		Early treatment
	All	Conservative			Cystectomy
		No BCG	BCG	p Value		p Value
	1,108	850	162		96
Men	851 (77%)	645 (76%)	127 (78%)	0.86	79 (82%)	0.88
Median Age (Interquartile Range)	75 (65-81)	76 (67-82)	71 (64-78)	1.8·10^-5	66 (60-71)	2.3·10^-5
No previous cancer*	996 (90%)	756 (89%)	151 (93%)	0.24	89 (92%)	0.92
Concomitant cis	142 (13%)	80 (9%)	36 (22%)	2.2·10^-4	26 (27%)	1.1·10^-3
WHO High Grade (HG) at T1 diagnosis**	903 (81%)	663 (78%)	152 (94%)	1.1·10^-5	88 (92%)	6.4·10^-3
Muscle in specimen at T1 diagnosis**	963 (87%)	491 (85%)	286 (88%)	0.63	91 (91%)	0.29

*no other cancer within 5 years before BC diagnosis.

**in any TURB within 3 month since first T1 diagnosis.

Figure 2. Cause-specific survival (CSS) and overall survival (OS) of T1 BC patients in Norway.

Table 3. Results from the cause-specific and overall survival analysis. A hazard ratio HR > 1 indicates a higher mortality risk compared to the reference group, HR < 1 a lower risk respectively. We also provide confidence intervals (CI) and p-values.

		Cause-specific survival			Overall survival
		HR	CI	p Value	HR	CI	p Value
Age	<65	1			1
	65-74	1.53	0.85-2.76	0.16	2.06	1.23-2.99	1.5·10^−4
	75-80	2.60	1.48-4.58	9.2·10^−4	3.76	2.63-5.37	4.2·10^−13
	>80	5.64	3.31-9.59	1.9·10^−10	7.18	5.07-10.2	1.1·10^−28
Sex	Men	1			1
	Women	0.89	0.63-1.26	0.50	0.74	0.59-0.92	7.0·10^−3
WHO	LG	1			1
	HG	1.58	1.03-2.42	0.034	1.73	1.33-2.24	3.6·10^−5
Concomitant cis	No	1			1
	Yes	0.96	0.59-1.59	0.88	1.02	0.77-1.37	0.88
Early treatment	Conservative Without BCG*	1			1
	Conservative With BCG**	0.64	0.38-1.08	0.094	0.63	0.46-0.87	5.3·10^−3
	Cystectomy***	0.77	0.38-1.56	0.47	0.74	0.49-1.13	0.16

*conservative treatment without BCG within 8 weeks.

**conservative treatment with BCG within 8 weeks.

***cystectomy within 6 month.

Figure 3. Cancer-specific survival for T1 BC patients in Norway dependent on combined early and delayed treatment.